Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 3/20 | 0.37 |
| ▸ | CTSB | P07858 | 3/20 | 0.37 |
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | SLC18A2 | Q05940 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2699307 | 1.00 | CPB1 (0.41) | CPB1CASP3CTSBCTSKCTSL | |
| SCHEMBL704762 | 0.93 | CPB1 (0.49) | CPB1CASP3CTSBCTSKCTSL | |
| SCHEMBL703729 | 0.93 | CPB1 (0.49) | CPB1CASP3CTSBCTSKCTSL | |
| SCHEMBL708864 | 0.83 | ACKR3 (0.35) | ACKR3KCNH2SLC18A2HTR2ASLC6A3 | |
| SCHEMBL703730 | 0.83 | CPB1 (0.38) | CPB1CASP3CTSBCTSKCTSL | |
| SCHEMBL704763 | 0.83 | CPB1 (0.38) | CPB1CASP3CTSBCTSKCTSL | |
| SCHEMBL2698574 | 0.78 | GRIN1 (0.33) | KCNH2SLC18A2HTR2ASLC6A3 | |
| SCHEMBL2700729 | 0.78 | GRIN1 (0.33) | KCNH2SLC18A2HTR2ASLC6A3 | |
| SCHEMBL2698668 | 0.77 | CPB1 (0.51) | CPB1CASP3CTSBCTSKCTSL | |
| SCHEMBL2699151 | 0.77 | CPB1 (0.51) | CPB1CASP3CTSBCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | CPB1 1228/4885CASP3 487/4885CTSB 308/4885 |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | CPB1 1228/4885CASP3 487/4885CTSB 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.